Relative and age-dependent stimulation of soluble and cellular immunity in opiate dependence

Journal of Addiction Medicine

Volumn 6, Issue 1, 2012, Pages 10-17

  Reece, Albert S ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Immunosenescence; Immunostimulation; Immunosuppression

Indexed keywords

C REACTIVE PROTEIN; GLOBULIN;

ADULT; AGE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOSTIMULATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL COUNT; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBOCYTE COUNT;

ADULT; AGE FACTORS; AGED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOCOMPETENCE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; OPIOID-RELATED DISORDERS; PLATELET COUNT; RECURRENCE; REFERENCE VALUES; RETREATMENT; SERUM GLOBULINS; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84863693998     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31822c3bf4     Document Type: Article

References (48)

1. Adler MW, Geller EB, Chen X, Rogers TJ. Viewing chemokines as a third major system of communication in the brain. AAPS J 2005;7:E865-E870.
2. AIHW. National Comorbidity Initiative: A Review of Data Collections Relating to People With Coexisting Substance Use and Mental Health Disorders. Canberra, Australia; Australian Institute of Health and Welfare; 2005.
3. Baker KD, Lubman DI, Cosgrave EM, et al. Impact of co-occurring substance useon6month outcomes for young people seeking mental health treatment. Aust N Z J Psychiatry 2007;41:896-902.
4. Beck JD, Eke P, Heiss G, et al. Periodontal disease and coronary heart disease: a reappraisal of the exposure. Circulation 2005;112:19-24.
5. Boren E, Gershwin ME. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 2004;3:401-406.
6. Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw Hill, 2006.
7. Buchanan MM, Hutchinson M, Watkins LR, Yin H. Toll-like receptor 4 in CNS pathologies. J Neurochem 2010;114:13-27.
8. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006;1:280-295.
9. Cawson RA, Odell EW, Porter S. Cawson's Essentials of Oral Pathology and Oral Medicine. New York: Churchill Livingstone, 2002.
10. Ceriello A, Giugliano D, Passariello N, et al. Impaired glucose metabolism in heroin and methadone users. Horm Metab Res 1987;19:430-433.
11. Chien KR, Karsenty G. Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell 2005;120:533-544.
12. Darke S, Kaye S, Duflou J. Systemic disease among cases of fatal opioid toxicity. Addiction 2006;101:1299-1305.
13. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15.
14. Delaloye J, Roger T, Steiner-Tardivel QG, et al. Innate immune sensing of modified vaccinia virusAnkara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009;5:e1000480.
15. Desvarieux M, Demmer RT, Rundek T, et al. Periodontal microbiota and carotid intima-media thickness: the oral infections and vascular disease epidemiology study (INVEST). Circulation 2005;111:576-582.
16. Fahmy MS, Sadeghi A, Behmard S. Epidemiologic study of oral cancer in Fars Province, Iran. Community Dent Oral Epidemiol 1983;11:50-58.
17. Fauci AS, Braunwald E, Kapser DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw Hill, 2008.
18. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000;908:244-254.
19. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007;128:92-105.
20. Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995;16:12-16.
21. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000;71:1554-1560.
22. Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med 2006;7:389-396.
23. Hser YI, Gelberg L, Hoffman V, Grella CE, Mccarthy W, Anglin MD. Health conditions among aging narcotics addicts: medical examination results. J Behav Med 2004;27:607-622.
24. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 2008;28:20-29.
25. Kidd EAM. Essentials of Dental Caries: The Disease and Its Management. Oxford, England: Oxford University Press, 2002.
26. Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006;85:258-262.
27. Lewis SS, Hutchinson MR, Rezvani N, et al. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience 2010;165:569-583.
28. Claude B. Lecons Sur Le Diabete et la Glycogenese Animale. Paris: Cours de Medecine, 1877.
29. Mccarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001;62:111-123.
30. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009;10:23-36.
31. Mousavi MR, Damghani MA, Haghdoust AA, Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope 2003;113:1939-1943.
32. Neri S, Bruno CM, Pulvirenti D, et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl) 2005;179:700-704.
33. Newman MG, Takei HH, Carranza FA. Carranza's Clinical Periodontology. London: W. B. Saunders & Co, 2002.
34. Pillai R, Nair BS, Watson RR. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch Toxicol 1991;65:609-617.
35. Reece AS. Dental health in addiction. Aust Dent J 2009;54:185-186.
36. Reece AS. Dentition of addiction in Queensland: poor dental status and major contributing drugs. Aust Dent J 2007a; 52:144-149.
37. Reece AS. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immun Ageing 2007b; 4:6-15.
38. Reece AS. Hair graying in substance addiction. Arch Dermatol 2007c; 143:116-118.
39. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007d; 2:35.
40. Reece AS. Chronic immune stimulation as a contributing cause of chronic disease inopiate addiction including multi-system ageing. Med Hypotheses 2010;75:613-619.
41. Reece AS, Davidson P. Deficit of circulating stem-progenitor cells in opiate addiction: a pilot study. Subst Abuse Treat Prev Policy 2007;2:19-28.
42. Rosen D, Smith ML, Reynolds CF III. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry 2008;16:488-497.
43. Sadeghi A, Behmard S. Cancer of the bladder in Southern Iran. Cancer 1978;42:353-356.
44. Sadeghi A, Behmard S, Shafiepoor H, Zeighmani E. Cancer of the esophagus in southern Iran. Cancer 1977;40:841-845.
45. Sadeghian S, Darvish S, Davoodi G, et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2007;14:715-717.
46. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009;30:581-591.
47. Wilson NS, Behrens GM, Lundie RJ, et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs crosspresentation and antiviral immunity. Nat Immunol 2006;7:165-172.
48. + T cell response. PLoS Pathog 2010;6:e1000768.